[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"illness-anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:illness-anxiety-disorder":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,72],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100431561",false,"NCT04899687","Study of Dextromethorphan in OCD and Related Disorders","Fluoxetine\u002FDextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study","Inclusion Criteria:\n\n* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)\n* Living within California\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Current bipolar disorder or psychotic disorder\n* Active moderate or severe substance use disorder, lifetime severe substance use disorder\n* Pregnant or nursing women\n* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start\n* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.",[26,27,28,29],"Obsessive-Compulsive Disorder","Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[31,32,33,34,35,36],"OCD","BDD","IAD","SSD","Fluoxetine","Dextromethorphan","RECRUITING","2026-05-18",{"date":40,"type":41},"2026-05-20","ACTUAL",{"date":43,"type":41},"2022-01-20",{"date":45,"type":20},"2028-12-01",{"name":47,"class":48},"Stanford University","OTHER",1,{"id":51,"slug":4,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":49},"100356252","NCT03918577","Caloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum Disorders","Inclusion Criteria:\n\n* Age 18-65\n* Primary diagnosis of Obsessive-Compulsive Disorder, Body Dysmorphic Disorder, Illness Anxiety Disorder or Somatic Symptom Disorder (excluding \"with predominant pain\")\n* Strongly held OCRD-related concerns meeting BABS score criterion.\n* No recent change in psychopharmacological treatment, if any\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Psychiatric or medical conditions (eg, vertigo, history of otological surgery) that might make participation unsafe\n* Pregnant or nursing women\n* Active or recent substance use",{"count":56,"type":20},16,[58],"NA","This study investigates whether caloric vestibular stimulation can modulate a measure of insight in obsessive-compulsive spectrum disorders.",[26,28,27],[62,63],"Caloric Vestibular Stimulation","Insight","2026-01-21",{"date":66,"type":41},"2026-01-22",{"date":68,"type":41},"2022-05-10",{"date":70,"type":20},"2026-12-30",{"name":47,"class":48},{"id":73,"slug":4,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":79,"type":20},180,[58],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[83,84,85,86,87,27,88,89,90,91],"Anxiety Disorders","Trauma","Generalized Anxiety Disorder","Panic Disorder","Agoraphobia","Social Anxiety Disorder","Posttraumatic Stress Disorder","Acute Stress Disorder","Adjustment Disorder With Anxious Mood",[93,94,95,96],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":99,"type":41},"2025-08-24",{"date":101,"type":41},"2022-08-22",{"date":103,"type":20},"2027-05",{"name":105,"class":48},"University of Texas at Austin",""]